Holsinger Leslie 4
4 · Cortexyme, Inc. · Filed Dec 15, 2020
Insider Transaction Report
Form 4
Cortexyme, Inc.CRTX
Holsinger Leslie
Executive Vice President
Transactions
- Exercise/Conversion
Common Stock
2020-12-14$0.27/sh+40,000$10,800→ 43,500 total - Sale
Common Stock
2020-12-14$28.80/sh−1,700$48,960→ 41,800 total - Sale
Common Stock
2020-12-14$30.15/sh−14,275$430,391→ 27,525 total - Sale
Common Stock
2020-12-14$30.91/sh−13,200$408,012→ 14,325 total - Sale
Common Stock
2020-12-14$31.79/sh−9,525$302,800→ 1,800 total - Sale
Common Stock
2020-12-14$32.59/sh−400$13,034→ 4,400 total - Sale
Common Stock
2020-12-14$32.59/sh−900$29,331→ 3,500 total - Award
Stock Option (Right to Buy)
2020-12-11+100,000→ 100,000 totalExercise: $29.60Exp: 2030-12-10→ Common Stock (100,000 underlying) - Award
Stock Option (Right to Buy)
2020-12-11+100,000→ 100,000 totalExercise: $29.60Exp: 2030-12-10→ Common Stock (100,000 underlying) - Exercise/Conversion
Stock Option (Right to Buy)
2020-12-14−40,000→ 66,794 totalExercise: $0.27Exp: 2026-05-09→ Common Stock (40,000 underlying)
Footnotes (4)
- [F1]The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 29, 2020.
- [F2]The shares subject to the option vest in 48 equal monthly installments from the vesting commencement date, subject to the grantee's continuous service to the Issuer on each such date.
- [F3]50% of the shares will vest on March 31, 2023 provided that the Issuer's Compensation Committee has determined that Performance Condition No. 1 (as defined below) has been met, and 50% of the shares will vest on March 31, 2024 provided that the Issuer's Compensation Committee has determined that Performance Condition No. 2 (as defined below) has been met; provided further that, in each case, the grantee will have been continuously a service provider from the date of grant through each such vesting date. Performance Condition No. 1 means that the average closing price per share of the Issuer's common stock in any 45 consecutive trading day period prior to March 15, 2023 has exceeded $135 per share. Performance Condition No. 2 means that the average closing price per share of the Issuer's common stock in any 45 consecutive trading day period prior to March 15, 2024 has exceeded $170 per share.
- [F4]The option vested at the rate of 25% of the shares on April 4, 2017, and the remaining 75% of shares vested in equal monthly installments beginning on May 4, 2017 until all the shares were fully vested on April 4, 2020.